EUVIMEDSkopri EUVIMED
Übersichtsarbeit

Resistance to immune checkpoint inhibitors and the tumor microenvironment

Shusuke Kawashima, Yosuke Togashi iD

Experimental Dermatology · 2023-03 · 32 (3) · 240-249

DOI: 10.1111/exd.14716 ↗

At a glance

Übersichtsarbeit in Experimental Dermatology, published online on 2022-12-08. Written by Shusuke Kawashima and 1 co-authors. Institution: Department of Dermatology, Graduate School of Medicine, Chiba University, Chiba, Japan. Major MEDLINE topics: Neoplasms, Skin Neoplasms. Cited 48 times so far (Crossref); 117 references. Funded by: Japan Agency for Medical Research and Development, Japan Science and Technology Agency, Japan Society for the Promotion of Science.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Immune checkpoint inhibitors (ICIs) have contributed significantly to the treatment of various types of cancer, including skin cancer. However, not all patients respond; some patients do not respond at all (primary resistance), while others experience recurrence after the initial response (acquired resistance). Therefore, overcoming ICI resistance is an urgent priority. Numerous ICI resistance mechanisms have been reported. They are seemingly quite complex, varying from patient to patient. However, most involve T‐cell activation processes, especially in the tumor microenvironment (TME). ICIs exert their effects in the TME by reactivating suppressed T cells through inhibition of immune checkpoint molecules, such as cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) and programmed cell death protein 1 (PD‐1). Thus, this review focuses on the resistance mechanisms based on the T‐cell activation process. Here, we classify the main mechanisms of ICI resistance into three categories based on (1) antigen recognition, (2) T‐cell migration and infiltration, and (3) effector functions of T cells. By identifying and understanding these resistance mechanisms individually, including unknown mechanisms, we seek to contribute to the development of novel treatments to overcome ICI resistance.

Subjects

MeSH terms (MEDLINE)

NeoplasmsSkin NeoplasmsHumansImmune Checkpoint InhibitorsTumor MicroenvironmentImmunotherapy

Author keywords

acquired resistanceantitumor immunityimmune checkpoint inhibitorsprimary resistancetumor microenvironment

Substances

Immune Checkpoint Inhibitors

Authors and institutions

  • Department of Dermatology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Chiba Cancer Center, Research Institute, Chiba, Japan.
  • Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.

ORCID profiles: Yosuke Togashi

Funding

  • Japan Agency for Medical Research and Development
  • Japan Science and Technology Agency
  • Japan Society for the Promotion of Science

Cite

APA

Kawashima, S., & Togashi, Y. (2023). Resistance to immune checkpoint inhibitors and the tumor microenvironment. Experimental Dermatology, 32(3), 240-249. https://doi.org/10.1111/exd.14716

Vancouver

Kawashima S, Togashi Y. Resistance to immune checkpoint inhibitors and the tumor microenvironment. Experimental Dermatology. 2023;32(3):240-249. doi:10.1111/exd.14716

BibTeX
@article{Kawashima2023,
  author = {Kawashima, Shusuke and Togashi, Yosuke},
  title = {Resistance to immune checkpoint inhibitors and the tumor microenvironment},
  journal = {Experimental Dermatology},
  year = {2023},
  volume = {32},
  number = {3},
  pages = {240--249},
  doi = {10.1111/exd.14716}
}
Start for free →